BeiGene Ltd

BGNE

NASDAQ. Currency in USD

197.00 -3.78 ( -1.88% )

Real time prices: December 09

Market Cap.
20.46B
Beta (5Y monthly)
0.85
Price/Earnings
-
EPS (TTM)
-21.35
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
312,773
1y Target Est.
260.98
Day's Range
196.93
-
207.86
52 Week's Range
118.18
-
296.01

Historical Summary

Performance
EPS growth
Share Buybacks

About BeiGene Ltd

Sector
Healthcare
Industry
Biotechnology
Website
https://www.beigene.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
102.71M
Employees
9000
Address
55 Cambridge Parkway, Cambridge, MA, United States, 02142
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Latest news

Why Shares of BeiGene Were Up Wednesday
Why Shares of BeiGene Were Up Wednesday

The Chinese pharmaceutical stock is experiencing a comeback.
By The Motley Fool - 1 week ago

Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session

Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:...
By Benzinga - 1 week ago

Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here...
By Benzinga - 1 week ago

Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket

Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading...
By Benzinga - 1 week ago

Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday

U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here...
By Benzinga - 2 weeks ago

What 4 Analyst Ratings Have To Say About BeiGene
What 4 Analyst Ratings Have To Say About BeiGene

Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: Bullish Somewhat...
By Benzinga - 4 weeks ago

Is This Chinese Pharmaceutical Stock Worth the Risk?
Is This Chinese Pharmaceutical Stock Worth the Risk?

BeiGene's shares are down this year, but it has two potential blockbusters.
By The Motley Fool - 5 weeks ago